Clinical RoundupFree Study shows screening population for select genes is a cost-effective solution January 19, 2018Vol.44 No.03
Clinical RoundupFree Polygenic hazard score predicts when men develop prostate cancer January 19, 2018Vol.44 No.03
Clinical RoundupFree Exelixis and Ipsen announce phase III trial results of Cabozantinib in advanced hepatocellular carcinoma January 19, 2018Vol.44 No.03
FreeIn Brief Kathy Albain receives first Huizenga Family Endowed Chair at Loyola University Chicago January 19, 2018Vol.44 No.03
FreeIn Brief ACS CAN: Cancer patients should be exempt from possible Medicaid work requirements January 19, 2018Vol.44 No.03
FreeIn Brief ACCC’s 2017 survey: cost of treatment is top threat to cancer program growth January 19, 2018Vol.44 No.03
FreeNews Analysis As government shutdown looms, don’t lose sight of bigger battle over appropriations, sequestration January 19, 2018Vol.44 No.03By Paul Goldberg
FreeGuest Editorial A unique drug for each patient:a paradigm shift in cancer therapy January 19, 2018Vol.44 No.03By Steven A. Rosenberg
Drugs & TargetsFree FDA expands indications for AZ’s Lynparza, making it first treatment for breast cancer with BRCA mutation January 12, 2018Vol.44 No.02
